7 results about "Lipodystrophy" patented technology

Provided herein are anti-Activin E antibodies having specific complementarity determining regions (CDRs) for the heavy and light chains, heavy and light chains, antigen binding fragments thereof, polynucleotides that encode the same, vectors, and host cells, and methods for treating a metabolic disorder, type 2 diabetes, obesity, an elevated triglyceride level, lipodystrophy, liver inflammation, fatty liver disease, hypercholesterolemia, an elevated liver enzyme, nonalcoholic steatohepatitis (NASH), a cardiovascular disease, cardiomyopathy, high blood pressure, and / or heart failure with the anti-Activin E antibodies disclosed herein.

Disclosed are devitalized adipose tissue. Disclosed are compositions comprising devitalized adipose tissue. In some aspects, the compositions further comprise a cryopreservation or lyophilization solution. Disclosed are cryopreserved or lyophilized devitalized adipose tissue. Disclosed are methods of augmenting a soft tissue site of a subject in need thereof comprising administering to the subject a composition comprising devitalized adipose tissue. Disclosed are methods of treating a subject having fat pad atrophy comprising administering to the subject a composition comprising devitalized adipose tissue. Disclosed are methods of treating a subject having lipodystrophy comprising administering to the subject a composition comprising devitalized adipose tissue. Disclosed are methods of treating a subject having a metabolic disease or condition comprising administering to the subject a composition comprising devitalized adipose tissue.

An sgRNA targeting a porcine PLIN1 gene and use thereof. The sgRNA action site is located on the second exon and the fourth exon of the porcine PLIN1 gene. Provided is a method for knocking out a PLIN1 gene in a porcine fetal fibroblast cell line by using a CRISPR / CAS9 system. The method comprises designing and synthesizing an sgRNA targeting a porcine PLIN1 gene according to a porcine PLIN1 gene sequence, then constructing a CRISPR / Cas9 targeting vector containing the sgRNA, and transferring same into a porcine fetal fibroblast cell to obtain a PLIN1 gene-knocked-out porcine fetal fibroblast cell. The cell can be used for the preparation of a PLIN1 gene-edited porcine, and is not only of great significance for porcine breeding, but also of great reference value for revealing the occurrence mechanism of human hereditary lipodystrophy and seeking a treatment method.

The invention relates to the technical field of animal models, and particularly discloses a construction method and application of a mouse model with fat dystrophy complicated with atherosclerosis, and the construction method comprises the following steps: mating MED1flox / flox mice with Adipoq-CreERT2 mice to obtain F1-generation mice; the F1-generation mice and MED1flox / flox mice are subjected to backcross, the mice with the genotype being MED1fl / flAdipoq-Cre < + / -> are screened, tamoxifen is injected to induce fat cell specific Cre recombinase expression, and fat cell specific MED1 gene knockout mice are obtained; and performing caudal vein injection of AAV8-PCSK9 virus and feeding with a high-cholesterol and high-fat feed to obtain the fat dystrophy complicated with atherosclerosis mouse model. According to the method provided by the invention, the mouse model with fat dystrophy complicated with atherosclerosis is successfully constructed and obtained, and collaborative simulation and regulation of phenotypes of two diseases are realized.

Provided herein are anti-Activin E antibodies having specific complementarity determining regions (CDRs) for the heavy and light chains, heavy and light chains, antigen binding fragments thereof, polynucleotides that encode the same, vectors, and host cells, and methods for treating a metabolic disorder, type 2 diabetes, obesity, an elevated triglyceride level, lipodystrophy, liver inflammation, fatty liver disease, hypercholesterolemia, an elevated liver enzyme, nonalcoholic steatohepatitis (NASH), a cardiovascular disease, cardiomyopathy, high blood pressure, and / or heart failure with the anti-Activin E antibodies disclosed herein.

Provided herein are therapeutic methods for treatment using an agonist leptin receptor (LEPR) antibody, an antigen-binding fragment thereof, or a composition comprising the LEPR antibody or an antigen-binding fragment thereof. Such methods of treatment include treating conditions associated with metabolic dysfunction, including, for example, lipodystrophy, obesity predisposition or obesity, weight loss, non-alcoholic fatty liver disease, overappetite, hyperglycemia, insulin resistance, dyslipidemia, hepatic steatosis, and infertility.

Provided herein are therapeutic methods of treatment using an agonist leptin receptor (LEPR) antibody, antigen-binding fragment thereof, or a composition comprising the LEPR antibody or antigen-binding fragment thereof, to perform the treatment. Such therapeutic methods include treating conditions associated with metabolic dysfunction, including, for example, lipodystrophy, obesity predisposition or obesity, weight loss, nonalcoholic fatty liver disease, bulimia, hyperglycemia, insulin resistance, dyslipidemia, hepatic steatosis, and infertility.